Human stem cells have great potential for finding restoring damaged tissues throughout the body and speeding the drug discovery process. We are developing a combined approach of both the cells needed to restore the damaged area and using these cells in a Petri dish to discover new compounds to treat diseases such as Alzheimer's disease.
Through collaborations with others, including scientists at Georgia Tech and Emory, we are developing therapies and drug discovery tools. Animal stem cells and cloning benefits are far reaching, from treating race horse bone and cartilage damage to pig stem cells to treat diabetes in humans. Our platform technology will launch genetic progress in agricultural, veterinary and biomedical industries. Please visit the Stice Lab for more information.
Dr. Steven Stice awarded the highest scholastic faculty award; The D.W. Brooks Distinguished Professorship, is also a Georgia Research Alliance Eminent Scholar endowed chair, and Director of the Regenerative Bioscience Center at The University of Georgia (UGA). He has over 20 years of research and development experience in biotechnology and is a co-founder of five biotechnology companies, including ArunA Biomedical and SciStem, which he currently serves as Chief Scientific Officer. ArunA was the first company to commercialize a product derived from human pluripotent stem cells, and the company has developed stem cells that were used to facilitate approval of Pfizer’s current cognitive enhancing pharmaceuticals.
Prior to joining UGA, Dr. Stice was the co-founder and served as both CSO and CEO of Advanced Cell Technology, the only US company currently in human clinical trials using human pluripotent stem cells. Additionally he co-founded startups; Prolinia and Cytogenesis which later merged with what is now, ViaCyte.
Dr. Stice has led industry and academic research teams in the area of pluripotent stem cells for over 20 years. In 2001, his labs were first in deriving one set of the original human embryonic stem cell lines in collaboration with BresaGen, Inc. (BG01, 02 and 03), and these lines were placed on the first NIH human ESC registry. Dr. Stice produced the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie). In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle. This research led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle embryonic stem cells. His laboratories were one of only five NIH sponsored sites for training NIH investigators on the propagation, differentiation and use of hESC over a six year period.
- Developing Animal Cloning
- Genetic Engineering Technology
- Combination therapies for Alzheimer’s, ALS and Cardiovascular Disease
- Traumatic Brain Injury
- Fracture Healing and Complex Bone Injury
- Pluripotent Stem Cells
- Environmental Toxicology
- Publications by Steven Stice may be found at PubMed.
- Society of Toxicology (SOT): Mouse Pluripotent Stem Cell Motor Neurons Generate Robust Neural Network Activity on Microelectrode Arrays.
- SOT: Using Human-Derived Neural Cells As an In Vitro Model for Developmental Neurotoxicity following Exposure to Pesticides.
- SOT: MR Imaging of Human Neural Progenitor Stem Cells: an in vivo Longitudinal Model.
- SOT: Bisphenol A Effects on In Vitro Human Neural Development Was Window of Susceptibility Dependent.
- SOT: Metabolomics and neurite outgrowth as data rich developmental neurotoxicity assays in a pluripotent stem cell derived human neural model.